Crizanlizumab

Records for this ingredient, by country (identity only).

ATC B06AX01 · 6 markets · 6 records

Crizanlizumab 6 markets · 6 records Forms
Filters
MarketUS 1GB 1AU 1

US 1 records · 1 shown of 1 Source openFDA NDC Directory · Data as of 2026-10-23

  • 10 mg per mL / per unit basis not statedinjectionADAKVEO

GB 1 records · 1 shown of 1 Source NHSBSA dm+d · Data as of 2026-10-19

  • 100 mg/10 mLinjectionAdakveo 100mg/10ml concentrate for solution for infusion vials

AU 1 records · 1 shown of 1 Source TGA · Data as of 2026-10-28 · includes records with unknown status (not proof of sale)

  • 100 mg per mL / per unit basis not statedinjectionADAKVEO crizanlizumab 10 mg/mL concentrate for solution for infusion vial unknown

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.